Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: A case report

Miranda Verschraagen, Epie Boven, Ivon Zegers, Frederick H. Hausheer, Wim J F Van Der Vijgh

Research output: Contribution to journalArticle

Abstract

Purpose: BNP7787 (2′,2′-dithio-bis-ethane sulfonate sodium) is a novel protector against cisplatin-induced toxicities. The pharmacokinetics of BNP7787 and its metabolite mesna were investigated in plasma and ascites of a cancer patient. We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin. Methods: BNP7787 and mesna were measured as mesna in deproteinized plasma and ascites using high-performance liquid chromatography with an electrochemical detector provided with a wall-jet gold electrode. Results: After the i.v. administration of 41 g/m2 BNP7787, BNP7787 and mesna had a half-life of 1.5 and 3.4 h, respectively. The auc of mesna was approximately 8% of the AUC of BNP7787. Coadministration of cisplatin did not appear to influence the plasma concentration-time curves of BNP7787 and mesna. In ascites, approximately 0.02% of the BNP7787 dose was present as mesna, whereas approximately 4% of the dose was present as BNP7787 at the time of the maximum concentration. Conclusions: It can be concluded that the presence of ascites did not have a major impact on the pharmaco-kinetics of BNP7787 and coadministration of cisplatin did not influence the pharmacokinetics of BNP7787 and mesna.

Original languageEnglish (US)
Pages (from-to)525-529
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume51
Issue number6
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Mesna
Pharmacokinetics
Metabolites
Ascites
Plasmas
Cisplatin
2,2'-dithiodiethanesulfonic acid
High performance liquid chromatography
Gold
Area Under Curve
Half-Life
Toxicity

Keywords

  • Ascites
  • BNP7787
  • Mesna
  • Pharmacokinetics
  • Plasma

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Verschraagen, M., Boven, E., Zegers, I., Hausheer, F. H., & Van Der Vijgh, W. J. F. (2003). Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: A case report. Cancer Chemotherapy and Pharmacology, 51(6), 525-529.

Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites : A case report. / Verschraagen, Miranda; Boven, Epie; Zegers, Ivon; Hausheer, Frederick H.; Van Der Vijgh, Wim J F.

In: Cancer Chemotherapy and Pharmacology, Vol. 51, No. 6, 01.06.2003, p. 525-529.

Research output: Contribution to journalArticle

Verschraagen, M, Boven, E, Zegers, I, Hausheer, FH & Van Der Vijgh, WJF 2003, 'Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: A case report', Cancer Chemotherapy and Pharmacology, vol. 51, no. 6, pp. 525-529.
Verschraagen M, Boven E, Zegers I, Hausheer FH, Van Der Vijgh WJF. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: A case report. Cancer Chemotherapy and Pharmacology. 2003 Jun 1;51(6):525-529.
Verschraagen, Miranda ; Boven, Epie ; Zegers, Ivon ; Hausheer, Frederick H. ; Van Der Vijgh, Wim J F. / Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites : A case report. In: Cancer Chemotherapy and Pharmacology. 2003 ; Vol. 51, No. 6. pp. 525-529.
@article{1cd54d3602204453bd04d0485c83fb55,
title = "Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: A case report",
abstract = "Purpose: BNP7787 (2′,2′-dithio-bis-ethane sulfonate sodium) is a novel protector against cisplatin-induced toxicities. The pharmacokinetics of BNP7787 and its metabolite mesna were investigated in plasma and ascites of a cancer patient. We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin. Methods: BNP7787 and mesna were measured as mesna in deproteinized plasma and ascites using high-performance liquid chromatography with an electrochemical detector provided with a wall-jet gold electrode. Results: After the i.v. administration of 41 g/m2 BNP7787, BNP7787 and mesna had a half-life of 1.5 and 3.4 h, respectively. The auc∞ of mesna was approximately 8{\%} of the AUC∞ of BNP7787. Coadministration of cisplatin did not appear to influence the plasma concentration-time curves of BNP7787 and mesna. In ascites, approximately 0.02{\%} of the BNP7787 dose was present as mesna, whereas approximately 4{\%} of the dose was present as BNP7787 at the time of the maximum concentration. Conclusions: It can be concluded that the presence of ascites did not have a major impact on the pharmaco-kinetics of BNP7787 and coadministration of cisplatin did not influence the pharmacokinetics of BNP7787 and mesna.",
keywords = "Ascites, BNP7787, Mesna, Pharmacokinetics, Plasma",
author = "Miranda Verschraagen and Epie Boven and Ivon Zegers and Hausheer, {Frederick H.} and {Van Der Vijgh}, {Wim J F}",
year = "2003",
month = "6",
day = "1",
language = "English (US)",
volume = "51",
pages = "525--529",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites

T2 - A case report

AU - Verschraagen, Miranda

AU - Boven, Epie

AU - Zegers, Ivon

AU - Hausheer, Frederick H.

AU - Van Der Vijgh, Wim J F

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Purpose: BNP7787 (2′,2′-dithio-bis-ethane sulfonate sodium) is a novel protector against cisplatin-induced toxicities. The pharmacokinetics of BNP7787 and its metabolite mesna were investigated in plasma and ascites of a cancer patient. We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin. Methods: BNP7787 and mesna were measured as mesna in deproteinized plasma and ascites using high-performance liquid chromatography with an electrochemical detector provided with a wall-jet gold electrode. Results: After the i.v. administration of 41 g/m2 BNP7787, BNP7787 and mesna had a half-life of 1.5 and 3.4 h, respectively. The auc∞ of mesna was approximately 8% of the AUC∞ of BNP7787. Coadministration of cisplatin did not appear to influence the plasma concentration-time curves of BNP7787 and mesna. In ascites, approximately 0.02% of the BNP7787 dose was present as mesna, whereas approximately 4% of the dose was present as BNP7787 at the time of the maximum concentration. Conclusions: It can be concluded that the presence of ascites did not have a major impact on the pharmaco-kinetics of BNP7787 and coadministration of cisplatin did not influence the pharmacokinetics of BNP7787 and mesna.

AB - Purpose: BNP7787 (2′,2′-dithio-bis-ethane sulfonate sodium) is a novel protector against cisplatin-induced toxicities. The pharmacokinetics of BNP7787 and its metabolite mesna were investigated in plasma and ascites of a cancer patient. We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin. Methods: BNP7787 and mesna were measured as mesna in deproteinized plasma and ascites using high-performance liquid chromatography with an electrochemical detector provided with a wall-jet gold electrode. Results: After the i.v. administration of 41 g/m2 BNP7787, BNP7787 and mesna had a half-life of 1.5 and 3.4 h, respectively. The auc∞ of mesna was approximately 8% of the AUC∞ of BNP7787. Coadministration of cisplatin did not appear to influence the plasma concentration-time curves of BNP7787 and mesna. In ascites, approximately 0.02% of the BNP7787 dose was present as mesna, whereas approximately 4% of the dose was present as BNP7787 at the time of the maximum concentration. Conclusions: It can be concluded that the presence of ascites did not have a major impact on the pharmaco-kinetics of BNP7787 and coadministration of cisplatin did not influence the pharmacokinetics of BNP7787 and mesna.

KW - Ascites

KW - BNP7787

KW - Mesna

KW - Pharmacokinetics

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=0038727864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038727864&partnerID=8YFLogxK

M3 - Article

C2 - 12750838

AN - SCOPUS:0038727864

VL - 51

SP - 525

EP - 529

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -